How to Cite
Abstract
Since the first definition by Hellman and Weichselbaum in 1995, the concept of oligometastatic disease has been a crucial area of clinical oncology. At the same time, metastases-directed locally ablative treatment turned out to be an effective alternative to the surgical approach. Additionally, stereotactic body radiation therapy has demonstrated a high level of achieving local control over the metastatic process, resulting in improved patient survival outcomes compared to standard palliative treatment in these conditions, with low toxicity levels.
However, as of the present time, there is no consensus regarding the therapeutic and prognostic aspects of this disease.
References
Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878-86. doi:10.1016/j.ijrobp.2011.08.036.
Palma DA, Salama JK, Lo SS, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549-57. doi:10.1038/nrclinonc.2014.96.
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8-10. doi:10.1200/JCO.1995.13.1.8.
Szturz P, Nevens D, Vermorken JB. Oligometastatic disease management: finding the sweet spot. Front Oncol. 2020;10:617793. doi:10.3389/fonc.2020.617793.
McGahan JP, van Raalte VA. History of Ablation. In: vanSonnenberg E, McMullen WN, Solbiati L, et al, eds. Tumor Ablation. 2005:3-16. doi:10.1007/0-387-28674-8.
De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol. 2012;7(10):1547-55. doi:10.1097/JTO.0b013e318262caf6.
Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. The Lancet. 2004;363(9422):1665–72. doi:10.1016/S0140-6736(04)16250-8.
Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol. 2014;25(10):1954-1959. doi:10.1093/annonc/mdu370.
Engels B, Everaert H, Gevaert T, et al. Phase II study of helical tomotherapy for oligometastatic colorectal cancer. Ann Oncol. 2011;22(2):362-8. doi:10.1093/annonc/mdq385.
Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672-1682. doi:10.1016/S1470-2045(16)30532-0.
Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823-30. doi:10.1080/02841860600904854.
Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32(34):3824-30. doi:10.1200/JCO.2014.56.7412.
Milano MT, Zhang H, Metcalfe SK, et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115(3):601-8. doi:10.1007/s10549-008-0157-4.
Muacevic A, Kufeld M, Rist C, et al. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013;31(4):455-60. doi:10.1016/j.urolonc.2011.02.023.
Pasqualetti F, Panichi M, Sainato A, et al. [18F] Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016;11:9. doi:10.1186/s13014-016-0586-x.
Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34(6):861-70. doi:10.3109/02841869509127197.
Lax I, Blomgren H, Näslund I, et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33(6):677-83. doi:10.3109/02841869409121782.
Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998;82(6):1062-70. doi:10.1002/(sici)1097-0142(19980315)82:6<1062::aid-cncr8>3.0.co;2-g.
Goto T, Hirotsu Y, Mochizuki H, et al. Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile. Oncotarget. 2017;8(19):31133-31143. doi:10.18632/oncotarget.16096.
Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29(22):2972-7. doi:10.1200/JCO.2010.33.3906.
Goto T, Hirotsu Y, Mochizuki H, et al. Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report. BMC Cancer. 2017;17(1):65. doi:10.1186/s12885-017-3059-1.
Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28-37. doi:10.1016/S1470-2045(12)70510-7.
PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3773-3784. doi:10.1200/JCO.20.01255.
Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18-e28. doi:10.1016/S1470-2045(19)30718-1.
Szturz P, Vermorken JB. Oligometastatic cancer: key concepts and research opportunities for 2021 and beyond. Cancers. 2021;13(11):2518. doi:10.3390/cancers13112518.
Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. The Lancet Oncology. 2020;21(1):e18-28.
Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157-166. doi:10.1016/j.radonc.2020.04.003.
Lo SS, Cardenes HR, Teh BS, et al. Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev Anticancer Ther. 2008;8(12):1939-51. doi:10.1586/14737140.8.12.1939.
Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-6. doi:10.1001/jama.2010.261.
Boda-Heggemann J, Lohr F, Wenz F, et al. kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol. 2011;187(5):284-91. doi:10.1007/s00066-011-2236-4.
Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44-54. doi:10.1038/nrclinonc.2009.188.
Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005;8(2):89-91. doi:10.1016/j.ccr.2005.07.014.
Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845-1851. doi:10.1038/s41591-018-0232-2.
Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61. doi:10.1038/nm1523.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051-2058. doi:10.1016/S0140-6736(18)32487-5.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830-2838. doi:10.1200/JCO.20.00818.
Lehrer EJ, Singh R, Wang M, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. 2021;7(1):92-106. doi:10.1001/jamaoncol.2020.6146.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816. doi:10.1186/s12885-019-5977-6.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023